At the news
? NEUTRALIMPACT 2/10 3 filed Apr 1, 2026 at 16:10 ET
Jean-Jacques Bienaime, a director or significant insider of Ascendis Pharma, filed a Form 3 to report initial beneficial ownership of 9,160 ordinary shares and 172.35 warrants exercisable into shares, with a power of attorney granted to several executives to file SEC reports on his behalf. This is a routine initial filing for ownership disclosure and does not indicate any change in holdings or strategic direction.
- Jean-Jacques Bienaime filed Form 3 to report initial beneficial ownership as of March 23, 2026
- He holds 9,160 ordinary shares (including ADSs) and 172.35 warrants
- Warrants vest 25% on June 10, 2026, then in 36 equal monthly installments through 2035
- Power of attorney granted to six company executives, including CEO, CFO, and CLO, to file SEC forms on his behalf
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access